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Background: Recently a few cases of synovial sarcoma (SS) of the abdominal viscera have been reported, raising
awareness about the potential for confusion between this entity and KIT-negative gastrointestinal stromal tumors
(GIST). We report the clinicopathological, immunophenotypical and molecular features of fifteen more SS occurring
in the stomach (8 cases), epigastric region (one case), small intestine (one case), large intestine (three cases), involving
both the terminal ileum and the caecum (one case) and liver (one case).
Methods: Immunostains for SMA, DESMIN, CD34, CD117, S100, EMA, CK AE1/3, TLE1, CD56, CD99, BCL2, DOG1 were
performed. Rearrangement of SS18 gene region was screened in all cases: by conventional karyotype in one case, the
remaining cases were screened either by interphase FISH or Q-PCR or both.
Results: Ten patients were male and five female, with an age range of 17–61 years (median 44). Tumor size ranged
from 2 to 15 cm (median 8). Mitoses per 10 HPF ranged from 4 to 27 (median 9.5). Eleven tumors were monophasic
fibrous SS, one biphasic SS and three poorly differentiated SS. SMA, Desmin, CD34, CD117 and S100 were negative in all
cases, whereas EMA and/or CK AE1/AE3 were positive in all cases. TLE1, BCL2 and CD56 were positive in all tested
cases. DOG1 was positive in one case. SS18 gene region rearrangement was demonstrated in all cases. A fusion
transcript was amplified in eight cases: either SS18-SSX2 or SS18-SSX1 respectively in four cases each.
Conclusions: SS is increasingly recognized at visceral sites. Molecular analyses play a key role when dealing with usual
histotypes in unusual sites. Correct diagnosis is crucial for appropriate therapy.
Keywords: Synovial sarcomas, Pathology, Differential diagnosis, Digestive tract, SarcomaIntroduction
Synovial sarcoma (SS) is a mesenchymal malignant tumour
that accounts for approximately 10% of all soft tissue sar-
comas [1]. It usually occurs in the lower limbs of children
and young adults, with the knee region being the most
frequently affected area [1]. Three main histological vari-
ants of SS have been recognized: the monophasic, bi-
phasic and poorly differentiated subtypes [1]. Both the
monophasic and biphasic variants feature a spindle cell
population set in a variable collagenous background with* Correspondence: apdeitos@ulss.tv.it
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An epithelial component is present in the biphasic vari-
ant, with solid nests and glandular or tubular structures
[1]. The existence of a predominantly monophasic epithe-
lial pattern has been reported, too [2]. In approximately
20% of cases, SS exhibits undifferentiated, high-grade
morphology and is usually indicated as “poorly differenti-
ated” SS (PDSS) [3]. Three main groups of PDSS can be
identified: one exhibiting round cell morphology associ-
ated with necrosis and high mitotic count; another charac-
terized by the presence of larger cells, with polygonal
cytoplasm which may feature rhabdoid morphology; and a
third group presenting as high-grade spindle cell tumors
often featuring a “herringbone” growth pattern [3,4].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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location involving chromosomes X and 18. This transloca-
tion results in three alternative fusion products of the
SS18 gene (previously known as SYT) (on chromosome
18) with either SSX1, or SSX2 or SSX4 gene (on chromo-
some X) [1]. This knowledge provides useful ancillary
diagnostic tools [1] for identification of the specific trans-
location by interphase FISH analysis, with probes flanking
the breakpoints, and amplification of the specific chimeric
transcript by RT-PCR techniques [5].
SS rarely occurs in unusual sites including: the head
and neck region [6,7], mediastinum [8], larynx and hy-
popharynx [9], nerves [10], blood vessels [11,12], heart
[13], abdominal cavity [14], gastrointestinal tract [15-23]
and liver [24,25]. In routine activity it may be difficult to
distinguish SS occurring in the digestive tract from other
mesenchymal neoplasms, mainly GIST (gastrointestinal
stromal tumour). However, this distinction is crucial to
ensure a correct therapeutic approach. Here we report
the clinicopathological, immunohistochemical and mo-
lecular genetic data of fifteen cases of SS occurring in
the digestive system. We aim to improve knowledge on
this entity and stress the importance of correct differen-
tial diagnosis for appropriate therapeutic management.
Materials and methods
Patients
Fifteen cases of SS of the abdominal viscera were col-
lected from three Italian institutions, the consultation
files of one of the Authors (APDT) and Departments of
Pathology, The University of Texas M. D. Anderson
Cancer Center, Houston, TX, USA. Patients’ clinicalTable 1 Clinicopathologic features of 14 synovial sarcomas of
Case # Site Size Gen
1 Gastric body 8 F
2 Cardias 6 M
3 Gastric 2 M
4 Gastric NR M
5 Gastric 10 M
6 Gastric 10 M
7 Gastric 6 M
8 Gastric 3.8 F
9 Epigastrium 13 F
10 Ileum 8 M
11 Large bowel 5.5 M
12 Rectosigmoid colon 6.3 F
13 Rectosigmoid colon 6.3 F
14 Ileum/Colon 7.5 M
15 Liver 15 M
Legend: Size is given in centimeter; NR: not reported, Follow Up is in months; DOD
lost to follow up.records were retrieved. Follow-up information was avail-
able for 11 patients (Table 1). All samples were handled in
a coded fashion, and all procedures were performed ac-
cording to the ethical guidelines of the local institutions.
Pathology assessment and immunohistochemistry
All the cases were reviewed for diagnostic confirmation
and both necrosis extent and mitoses count evaluated,
grading provided according to French National Feder-
ation of Cancer Centers (FNLCC) (Table 2). In a subset
of cases neoadjuvant chemotherapy was applied and pre-
chemo biopsies were not available (Table 2); the values
for mitoses and necrosis are no longer relevant for these
cases as pre-treated specimens cannot be accurately
graded under the FNCLCC system.
Immunostaining was performed for EMA, cytokeratin
AE1/AE3, SMA, Desmin, CD34, CD117, S-100, CD99,
CD56 and TLE1. Four-μm sections of formalin-fixed
paraffin-embedded material were used according to
standard laboratory procedures. Details of the antibodies
used are given in Table 3.
Conventional karyotype
For case 14 conventional karyotype was performed. Cell
culture, harvest conditions, and karyotyping were per-
formed according to standard protocols.
Interphase FISH
Fluorescent in situ hybridisation (FISH) was performed
on 5 μm paraffin-embedded tissue sections using the
LSI SYT (18q11.2) Dual Color Break Apart Rearrange-
ment Probe set (Vysis, Downers Grove, IL, USA).the digestive system
















: dead of disease; NED: not evidence of disease; AWD: alive with disease; Lost:
Table 2 Morphological features of 15 synovial sarcomas of the digestive system
Case # Type Mitoses Necrosis Grading Involvement of
Perivisceral soft tissue Peritoneum Adjacent organ
1 M 7 1 2 None None None
2 PD 11 1 2 Adventitial tissue Yes None
3 M 6 0 2 None None None
4 M P P P Adventitial tissue Yes Pancreas
5 M 12 1 2 Adventitial tissue Yes Pancreas
6 M P P P None None None
7 B 27 1 3 None None None
8 M 14 1 2 None None None
9 M 8 2 3 Stomach, duodenum and liver Yes None
10 M 5 1 2 None None None
11 M 13 1 2 Perivisceral adipose tissue None None
12 PD P P P Perirectal adipose tissue None None
13 PD P P P None None None
14 M 4 1 2 None None None
15 M P P P None None None
Legend: M: monophasic, B: biphasic, PD: poorly differentiated, mitoses are per 10 HPF, P: pretreated. Necrosis is reported as: 0 for no necrosis, 1 for <50% tumor
necrosis, 2 for ≥ 50% tumor necrosis.
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turer’s protocol. Slides were mounted and counterstained
with anti-fade DAPI (Vysis, Downers Grove, IL, USA), vi-
sualized using an epifluorescent microscope (Olympus
BX61) and analysed with FISH analysis software (Genetix-
Cytovision 4.5.1). 300 interphase nuclei were analyzed.
Q-PCR
Ten to fifteen 15 μm-thick sections from paraffin-
embedded tissue were de-paraffinized twice using xy-
lene, washed twice with absolute ethanol followed by
TNE1X, resuspended in 250 μl of ATL buffer (Qiagen)
with the addition of proteinase K (Qiagen), and incu-
bated for 72 hours at 55°C under moderate shaking. TheTable 3 Details of the antibodies used in this study
Antibody Clone Producer
EMA E29 Dako, Glostrup, Denmark
CKAE1/AE3 Polyclonal Dako, Glostrup, Denmark
SMA 1A4 Dako, Glostrup, Denmark
DESM D33 Dako, Glostrup, Denmark
CD34 QBend-10 Dako, Glostrup, Denmark
CD117 Polyclonal Dako, Glostrup, Denmark
S-100 Polyclonal Dako, Glostrup, Denmark
TLE1 c-9121 Santa Cruz Biochemicals, San
BCL2 124 Dako, Glostrup, Denmark
CD56 123C3 Dako, Glostrup, Denmark
CD99 MIC2 Dako, Glostrup, Denmark
DOG1 K9 Novocastra, NewCastle, UKpercentage of tumor cells, as calculated from the HE-
stained slides, was at least 70%. Subsequently, RNA was
extracted with TRIzol-LS Reagent (Gibco BRL), accord-
ing to the manufacturer’s instructions. RNA pellets were
resuspended in 10–20 μl of RNAse-free water and stored
at −80°C. 5 μg of total RNA were reverse transcribed in
a total volume of 20 μl using specific reverse primers for
SSX and BETA2M genes, respectively. Samples were in-
cubated at 42°C for 1 hour, then at 72°C for 15 minutes.
PCR amplification of each sample and a 1:20 dilution
were performed in duplicate using 96-well plates in
25 μl reaction mixture containing 300 nM of each primer,
200 nM of each probe (SSX1-SSX2) or 100 nM probe
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OnePlus Real-Time PCR Systems (Applied Byosystem).
(For primer and probe sequences, see Table 4). Thermal
cycling conditions were 2 minutes at 50°C, 10 minutes at
95°C, then 50 cycles for three PCR steps consisting of
30 seconds at 95°C and 1 minute at 60°C. Eight cases were
studied by Q-PCR, for all of them a positive control prod-
uct was amplified.
Results
In the identified fourteen cases of digestive system SS a
male prevalence was found: male/female ratio was 3:1.
Age at clinical presentation ranged from 17 to 61 years
(median 44 years) (Table 1). Size ranged from 2 cm to
15 cm (median 8 cm) (Table 1). Eight cases were occur-
ring in the stomach, one case in the epigastric region,
one case in the ileum, three cases in the large intestine,
one case was involving both the terminal ileum and the
caecum and one case in the liver (Table 1).
Five of the eight tumors arising in the stomach tract
were confined to the wall (without serosal involvement);
one extended into the perivisceral soft tissue, periton-
eum and omentum (Figure 1A) and two involved the
pancreas (Table 2). The tumor located in the epigastric
region was adherent to the stomach and duodenal wall
and focally attached to the liver (Table 2). Three tumors
were involving the large bowel with extension in the
perivisceral adipose tissue in two of them. The case af-
fecting the ileum was limited to the ileum wall, similarly
also the case involving both ileum and caecum was lim-
ited to the visceral wall (Table 2). The one in the liver
was confined to the parenchyma without ulceration of
the Glisson’s capsule (Table 2).
Microscopically, eleven of the tumours consisted of
monotonous spindle cell proliferation, with scant intercel-
lular eosinophilic collagenous stroma (Figure 1B) (Table 2).
A focal HPC-like vascular network was observed. Three
cases showed poorly differentiated features (Figure 1C)
and one showed biphasic features with both spindle cells









BETA2M probe TGATGCTGCTTACATGTCTCGATCCCAMitotic count ranged from 4 to 27 mitoses/10 HPF
(median 9.5) (Table 2). Immunoreactivity for EMA
was found in all tested cases ranging from focal to
strong and diffuse (Figure 1D) (Table 5). Focal positiv-
ity for immunostains for cytokeratin AE1-AE3 was
found in 8 cases (Table 5). All tested cases were posi-
tive for TLE1, BCL2 and CD99 (Table 5). No expression
of CD117, SMA, DESMIN, CD34 and S-100 protein was
found. DOG1 was focally expressed in one case (case 9,
Table 5).
All cases showed SS18 gene region rearrangement.
Case 14 showed 46, XY, t(X; 18)(p11;q11) karyotype
(data not shown). The remaining cases were assessed ei-
ther by interphase FISH (Figure 1E) or by RT-PCR or
both. Eight cases were analyzed by RT-PCR: either SS18-
SSX2 fusion transcript or SS18-SSX1 fusion transcript
was identified in 4 cases each (Figure 1F, Table 5).
Follow up was available for 11 patients: range from 6
to 185 months (47 median) (Table 1).
Based on clinical, morphological, immunophenotypical
and molecular data a diagnosis of primary SS of the di-
gestive tract was formulated: monophasic synovial sar-
coma in eleven cases, biphasic SS in one case and poorly
differentiated SS in three cases.
Discussion
SS is characterized by a complex, relatively distinctive
immunophenotype, which includes co-expression of
mesenchymal (vimentin) and epithelial markers (cyto-
keratins and EMA). Since morphological features of epi-
thelial differentiation may be very subtle, immunostains
are a valuable diagnostic aid. Cytokeratins tend to decor-
ate most biphasic synovial sarcomas, but when dealing
with the monophasic subtype, the percentage of immu-
nopositivity falls to 60%-70%. Interestingly, cytokeratin
immunoreactivity has been demonstrated only in 50% of
PDSS [3] and high molecular weight cytokeratins proved
to be more sensitive than low molecular weight cytokera-
tins. The most sensitive marker of epithelial differentiation
is EMA, which stains most cases of PDSS, including those
that fail to express cytokeratins [3]. Between 30% and 60%
of SS express S-100 protein leading to potential confusion
when dealing with the differential diagnosis between
monophasic spindle-cell SS and MPNST [26,27]. To avoid
diagnostic pitfalls caused by the use of single antibody, it
is therefore strongly recommended to perform a panel of
immunohistochemical markers.
The diagnosis of biphasic synovial sarcoma is usually
straightforward, even for cases occurring in the digestive
system. Regarding monophasic SS in the digestive sys-
tem, the main differential diagnosis is with GIST: any
mesenchymal lesion arising in the GI tract would natur-
ally be suggestive of a diagnosis of GIST and CD117
negativity “per se” does not rule out such a possibility
Figure 1 Digestive tract SS features: A- Neoplastic cells were involving gastric wall with focal extension to nearby perivisceral soft
tissue and serosal ulceration (case 2, 12.5 X original magnification, HE staining). B- Most of the cases were composed of monomorphic
spindle cells (case 9, 400 X original magnification, HE staining). C- Poorly differentiated SS featuring monomorphic round cells with elevated
mitotic rate were encountered in 3 cases (case 4, 400 X original magnification, HE staining). D- Focal positivity for DOG1 staining was found in
one case(Case 9, 400 X original magnification). E- Interphase FISH showed split a part of the two signal in most of the nuclei (case 9, original
1000X magnification). F- A fusion transcript SS18-SSX1 was amplified by Q-PCR (plot showing the amplification curves of SS18-SSX1, SS18-SSX2
and beta-microglobulin).
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Table 5 Results of the performed immunostains and fusion type in 15 synovial sarcomas of the digestive system
Case # EMA CKAE1/AE3 SMA DESMIN CD34 CD117 S-100 BCL2 CD99 CD56 DOG1 TLE1 Fusion type
1 + - - - - - - + + + - + SS18-SSX1
2 + - - - - - - + + + - + N/A
3 + + - - - - - + + + - + N/A
4 + - NP NP NP - - NP NP NP NP NP N/A
5 + - NP - - - - NP NP NP NP NP SS18-SSX1
6 + - NP NP NP - - NP NP NP NP NP N/A
7 NP + NP NP - - NP NP NP NP NP NP SS18-SSX2
8 + + - - - - - + + + - + SS18-SSX1
9 + + - - - - - + + + + + N/A
10 + + - - - - - + + + - + SS18-SSX2
11 + - - - - - - + + + - + SS18-SSX2
12 + + NP NP NP - - + + NP NP NP SS18-SSX2
13 + + NP NP NP - - + + NP NP NP SS18-SSX1
14 + - NP - - - - + + NP NP NP N/A
15 + + - - - - - + + + - + N/A
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or epithelioid cells with perinuclear vacuolization and
nuclear palisading. Recognition of the histological fea-
tures, and the combination of CD117 with DOG1 stain-
ing is sufficient in the majority of cases to confirm the
diagnosis of GIST [29]. However caution should be used
in interpreting the results of immunohistochemistry
since synovial sarcoma of the digestive system may show
focal positivity for DOG 1 [30], as also exemplified in
our case series. Remarkably sporadic GIST cases have
been reported to be positive for cytokeratin [31,32],
however EMA positivity is exceptional in GIST [23].
Leiomyosarcomas and malignant spindle cell melanomas
are considered in the differential diagnosis with mono-
phasic SS of the digestive system. However they are
characterized by a higher pleomorphism and stronger
immunostaining for smooth muscle markers and mela-
nocytic markers, respectively, can usually confirm the
diagnoses.
Sarcomatoid carcinoma may also be considered in the
differential diagnosis, however it often exhibits conspicu-
ous pleomorphism, stronger expression of epithelial
markers, and area of conventional carcinoma are often as-
sociated with the sarcomatoid component.
Gastrointestinal clear cell sarcoma may be very diffi-
cult to distinguish form digestive system SS [33,34], also
because, as previously mentioned, SS may be positive for
S100 staining [26,27]. However gastrointestinal clear cell
sarcomas are usually negative for epithelial markers and
show rearrangement of the EWSR1 gene [33,34]. Re-
markably clear cells sarcomas occurring in the gastro-
intestinal tract differ from clear cell sarcomas of the soft
tissue. In fact they display scattered osteoclast-type giantcells and only partial melanocytic differentiation, being
debated to be a separate entity. For this reason Stockman
et al. proposed to call it malignant gastrointestinal neu-
roectodermal tumor [33].
PD SS may resemble other small round cell tumors in-
cluding Ewing Sarcoma/PNET, neuroblastoma, rhabdo-
myosarcoma and lymphoma [1]. Remarkably CD99
antigen is found also in SS [35] and epithelial markers
may be absent in PDSS and focally present in Ewing
Sarcoma/PNET [1]. In this setting, demonstration of re-
arrangement of SSX18 or EWSR1 is crucial for differenti-
ating respectively PDSS from Ewing Sarcoma/PNET [1].
Also it should be remembered that CD99 positivity in syn-
ovial sarcomas does not feature the typical crisp mem-
brane staining most often observed in Ewing’s sarcoma.
Cytogenetically, all SS variants are characterized by the
reciprocal translocation t(X;18)(p11.2;q11.2), which leads,
at molecular level, to the fusion between the synovial sar-
coma translocation gene on chromosome 18 (SS18) and
one of the synovial sarcoma X breakpoint (SSX) genes on
chromosome X: SSX1, SSX2 and rarely with SSX4 [36-38].
Interestingly, the SS18-SSX1 translocation seems to be
associated with the biphasic type [39]. The SS18 gene is
unrelated to any other known gene but contains a
glutamine-proline-glycine-rich region, suggestive of a
transcriptional activation domain. The SSX1, SSX2 and
SSX4 genes are also unrelated to other known genes and
encode proteins that show a remarkable homology.
Despite initial attempt to correlate fusion type with a sig-
nificantly longer disease-free survival [39,40] morphological
grading is still the most important prognostic indicator
[41]. Furthermore, tumor size (>5 cm), presence of neural
infiltration and vascular invasion, p53 overexpression, and
Romeo et al. Clinical Sarcoma Research  (2015) 5:7 Page 7 of 8high Ki67 proliferation index identify subsets of SS pa-
tients with increased risk of tumor relapse [42-44].
Conclusions
Recognizing SS is of paramount importance to ensure
the right therapy, especially because SS is known to re-
spond to ifosfamide-based systemic treatments [45]. In
the clinical setting of SS of the digestive system the use
of ancillary molecular techniques improves the diagnos-
tic accuracy.
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